Waystar raised $968M after pricing its IPO at $21.50/share, the middle of a marketed range, giving the health care payments software maker a ~$3.6B market value
Context & Ripple Effects
Waystar’s public listing follows its earlier expansion into patient billing and payments through the Patientco acquisition, extending its revenue-cycle-management footprint beyond its original healthcare software position.
The offering also marks a new valuation reference point after EQT and Canada’s state pension fund acquired a majority stake in Waystar at a $2.7B valuation in 2019.
First-order effects
- Waystar raises $968M at $21.50 per share and enters public markets with an approximately $3.6B market value.
- The IPO gives investors a current market benchmark for a healthcare payments and revenue-cycle software provider.
Second-order effects
- Waystar’s trading and disclosure as a public company create a more visible comparable for private healthcare revenue-cycle and payments businesses.
- The transaction adds to a run of enterprise- and healthcare-software IPO reference points, including Tempus’s $410.7M offering, helping investors distinguish demand across software categories rather than treating them as one market.
Third-order effects
- If comparable software businesses continue reaching public markets at workable valuations, IPOs can again become a meaningful pricing and liquidity mechanism alongside private ownership for mature vertical-software companies.
- The more durable shift is toward public markets assigning category-specific valuations to software businesses whose value proposition spans operational workflow and payments; whether that persists depends on post-listing performance, not IPO pricing alone.
The trend: Waystar is one data point in the reopening of public-market valuation discovery for mature, sector-specific software companies.